7 completed, 3 terminated. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow varespladib methyl: new trials by email Literature Review of varespladib methyl trials Research Report on varespladib methyl
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form - Snakebite, Envenoming, Snake | Phase 2 | Completed | Ophirex, Inc. | 140 | 2023-05-30 | 2025-06-27 |
| Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite Varespladib Methyl, Placebo, Standard of care (SOC) - Snakebites, Envenoming | Phase 2 | Completed | Ophirex, Inc. | 95 | 2021-08-15 | 2025-07-01 |
| Study of Varespladib in Patients Hospitalized With Severe COVID-19 Varespladib, Placebo - Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 | Phase 2 | Terminated | Ophirex, Inc. | 18 | 2021-06-30 | 2025-05-15 |
| A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function varespladib methyl - Renal Impairment | Phase 1 | Terminated | Anthera Pharmaceuticals | 28 | 2011-06-01 | 2012-03-20 |
| Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects varespladib methyl - Healthy Volunteers | Phase 1 | Completed | Anthera Pharmaceuticals | 6 | 2011-06-01 | 2011-12-20 |
| VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome A-002, varespladib methyl, Placebo - Acute Coronary Syndrome | Phase 3 | Terminated | Anthera Pharmaceuticals | 5189 | 2010-05-01 | 2012-10-31 |
| FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes Varespladib Methyl (A-002) - Acute Coronary Syndrome | Phase 2 | Completed | Anthera Pharmaceuticals | 625 | 2008-07-01 | 2014-03-04 |
| sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial Varespladib (A-002), placebo - Coronary Artery Disease | Phase 2 | Completed | University Health Network, Toronto | 164 | 2007-10-01 | 2009-10-09 |
| PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease A-002 - Coronary Artery Disease | Phase 2 | Completed | Anthera Pharmaceuticals | 120 | 2007-09-01 | 2008-01-07 |
| PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease A-002 - Coronary Artery Disease (CAD) | Phase 2 | Completed | Anthera Pharmaceuticals | 400 | 2007-04-01 | 2010-02-02 |
Coronary Artery Disease (3) · Acute Coronary Syndrome (2) · Snake Bites (2) · Angina, Unstable (1) · Atherosclerosis (1) · COVID-19 (1) · Non-ST Elevated Myocardial Infarction (1) · Renal Insufficiency (1) · Respiratory Distress Syndrome (1) · ST Elevation Myocardial Infarction (1)
Anthera Pharmaceuticals (6) · Ophirex, Inc. (3) · University Health Network, Toronto (1)
United States (8) · Ukraine (3) · Canada (2) · Georgia (2) · India (2) · Russia (2) · Australia (1) · Czechia (1) · Germany (1) · Hungary (1) · Italy (1) · Lebanon (1) · Netherlands (1) · New Zealand (1) · Poland (1)
Matthew Lewin, MD, PhD (1) · Timothy F Platts-Mills, MD, MSc (1) · Timothy Platts-Mills, MD, MSc (1) · Vladimir Dzavik, MD (1)
PMID 19231633, PMID 20863951, PMID 21081550, PMID 21098449, PMID 24247616, PMID 40738154